Furthermore, the CDKN2A gene, a cyclin-dependent kinase 2A inhibitor capable of regulating the cell cycle and exhibiting tumour suppressor activity, was found to be downregulated in HSCs from patients with AML. Here, CDKN2A is linked to acute myeloid leukemia.